You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for sofosbuvir; velpatasvir; voxilaprevir and what is the scope of patent protection?

Sofosbuvir; velpatasvir; voxilaprevir is the generic ingredient in one branded drug marketed by Gilead Sciences Inc and is included in one NDA. There are nineteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Sofosbuvir; velpatasvir; voxilaprevir has six hundred and twenty patent family members in forty-nine countries.

One supplier is listed for this compound.

Summary for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR
Generic Entry Date for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Peking University People's HospitalPhase 4
Helwan UniversityPhase 4
Kirby InstitutePhase 4

See all SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR clinical trials

US Patents and Regulatory Information for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Gilead Sciences Inc VOSEVI sofosbuvir; velpatasvir; voxilaprevir TABLET;ORAL 209195-001 Jul 18, 2017 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

Country Patent Number Title Estimated Expiration
Moldova, Republic of 20130029 Compusi antivirali (Antiviral compounds) ⤷  Try a Trial
Denmark 2203462 ⤷  Try a Trial
Montenegro 02294 KRISTALNI (S)-IZOPROPIL 2-(((S)-(((2R,3R,4R,5R)-5-(2 ,4-DIOKS0-3,4-DIHIDROPIRIMIDIN-1-(2H)-IL )-4 - FLUOR0-3-HIDROKSI-4-METILTETRAHIDROFURAN-2- IL)METOKSI)(FENOKSI)FOSFORIL)AMINO)PROPANOAT (CRYSTALLINE (S)-ISOPROPYL 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN- 1-(2H)-YL)-4-FLUORO-3-HYDROXY-4-METHYLTETRAHYDROFURAN-2-YL)METHOXY) (PHENOXY)PHOSPHORYL)AMINO)PROPANOATE) ⤷  Try a Trial
European Patent Office 2610264 N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester et procédé pour sa production (N-[(2'r)-2'-deoxy-2'-fluoro-2'-methyl-p-phenyl-5'-uridylyl]-l-alanine 1-methylethyl ester and process for its production) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2430014 2016C/006 Belgium ⤷  Try a Trial PRODUCT NAME: LEDIPASVIR/SOFOSBUVIR; AUTHORISATION NUMBER AND DATE: EU/1/14/958 20141118
2203462 C201430078 Spain ⤷  Try a Trial PRODUCT NAME: SOFOSBUVIR; NATIONAL AUTHORISATION NUMBER: EU/1/13/894; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/894; DATE OF FIRST AUTHORISATION IN EEA: 20140116
2203462 C20140035 00135 Estonia ⤷  Try a Trial PRODUCT NAME: SOFOSBUVIIR
2203462 C20140035 Estonia ⤷  Try a Trial PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.